Calamos Advisors

Calamos Advisors’s enGene Therapeutics Warrants ENGNW Stock Holding History

Calamos Advisors’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-148,290	Closed	-$418K	–	1223
2025 Q4	$418K	Sell	148,290 -1,710	-1%	-$3.9K	﹤0.01%	786
2025 Q3	$108K	Hold	150,000	–	–	﹤0.01%	851
2025 Q2	$118K	Hold	150,000	–	–	﹤0.01%	842
2025 Q1	$96K	Hold	150,000	–	–	﹤0.01%	826
2024 Q4	$128K	Hold	150,000	–	–	﹤0.01%	813
2024 Q3	$214K	Hold	150,000	–	–	﹤0.01%	787
2024 Q2	$209K	Hold	150,000	–	–	﹤0.01%	785
2024 Q1	$780K	Sell	150,000 -100,000	-40%	-$305K	﹤0.01%	671
2023 Q4	$213K	Buy	+250,000	New	+$192K	﹤0.01%	749

Other funds holding ENGNW

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return

LMR Partners London, United Kingdom $10.9B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.36B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Saba Capital Management New York $3.12B AUM 13% 1-Year Est. Return

CSS LLC Chicago, Illinois $1.8B AUM 59.56% 1-Year Est. Return

Ionic Capital Management New York $119M AUM 48.26% 1-Year Est. Return